These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31041512)

  • 1. CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.
    Su L; Gao S; Tan Y; Lin H; Liu X; Liu S; Yang Y; Sun J; Li W
    Ann Hematol; 2019 Jul; 98(7):1641-1646. PubMed ID: 31041512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Restratifying the prognosis of acute myeloid leukemia patients with CEBPA double mutations based on CSF3R mutations and measurable residual disease].
    Su L; Tan YH; Lin H; Han W; Yang YP; Liu XL; Sun JN; Liu QJ; Gao SJ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1021-1027. PubMed ID: 36709108
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia.
    Wang B; Wen L; Wang Z; Chen S; Qiu H
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):393-404. PubMed ID: 34975010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
    Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
    Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
    Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
    Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
    Maxson JE; Ries RE; Wang YC; Gerbing RB; Kolb EA; Thompson SL; Guidry Auvil JM; Marra MA; Ma Y; Zong Z; Mungall AJ; Moore R; Long W; Gesuwan P; Davidsen TM; Hermida LC; Hughes SB; Farrar JE; Radich JP; Smith MA; Gerhard DS; Gamis AS; Alonzo TA; Meshinchi S
    Blood; 2016 Jun; 127(24):3094-8. PubMed ID: 27143256
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
    Lavallée VP; Krosl J; Lemieux S; Boucher G; Gendron P; Pabst C; Boivin I; Marinier A; Guidos CJ; Meloche S; Hébert J; Sauvageau G
    Blood; 2016 Jun; 127(24):3054-61. PubMed ID: 27034432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
    Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.
    Braun TP; Okhovat M; Coblentz C; Carratt SA; Foley A; Schonrock Z; Curtiss BM; Nevonen K; Davis B; Garcia B; LaTocha D; Weeder BR; Grzadkowski MR; Estabrook JC; Manning HG; Watanabe-Smith K; Jeng S; Smith JL; Leonti AR; Ries RE; McWeeney S; Di Genua C; Drissen R; Nerlov C; Meshinchi S; Carbone L; Druker BJ; Maxson JE
    Nat Commun; 2019 Nov; 10(1):5455. PubMed ID: 31784538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical characteristics and prognosis of Chinese acute myeloid leukemia patients with CSF3R mutations.
    Chen X; Xu J; Fang F; Xu Z; Tan Y; Chang J; Muyey DM; Wang H
    Int J Lab Hematol; 2022 Apr; 44(2):364-370. PubMed ID: 34818692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational spectrum of acute myeloid leukemia patients with double
    Su L; Tan Y; Lin H; Liu X; Yu L; Yang Y; Liu S; Bai O; Yang Y; Jin F; Sun J; Liu C; Liu Q; Gao S; Li W
    Oncotarget; 2018 May; 9(38):24970-24979. PubMed ID: 29861846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia.
    Wang T; Hua H; Wang Z; Wang B; Cao L; Qin W; Wu P; Cai X; Chao H; Lu X
    Hematology; 2022 Dec; 27(1):994-1002. PubMed ID: 36066283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and impact of colony stimulating factor 3 receptor (CSF3R) mutations among Egyptian acute myeloid leukemia patients.
    Aref S; El-Ghonemy M; Abouzeid T; El-Sabbagh A; El-Baiomy M
    Leuk Res; 2014 Jun; 38(6):722-5. PubMed ID: 24746896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of
    Li RQ; Wen XL; Zhang XL; Dong CX; Wang MF; Liu XX; Huang YJ; Tan YH; Chang JM; Zhang RJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):628-632. PubMed ID: 37356918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia.
    Zhao Y; Huang Y; Jiang L; Zhang Y; Liu F; Yan P; Yu G; Liu J; Jiang X
    Ann Hematol; 2024 Sep; 103(9):3595-3604. PubMed ID: 39020042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
    Wei H; Zhou C; Liu B; Lin D; Li Y; Wei S; Gong B; Zhang G; Liu K; Gong X; Fang Q; Liu Y; Qiu S; Gu R; Song Z; Chen J; Yang M; Zhang J; Jin J; Wang Y; Mi Y; Wang J
    Br J Haematol; 2022 May; 197(4):442-451. PubMed ID: 35274287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.